<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="7b45a1d7-c3a5-4434-a848-45638cedd6e1"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use BELLADONNA AND OPIUM SUPPOSITORIES safely and effectively.  See full prescribing information for BELLADONNA AND OPIUM SUPPOSITORIES.<br/>
      <content styleCode="bold">BELLADONNA and OPIUM suppositories, for rectal use, CII</content>
      <br/>Initial U.S. Approval: 1938</title>
   <effectiveTime value="20230401"/>
   <setId root="8301e76b-134a-43d2-a7dc-c600ccf2695c"/>
   <versionNumber value="10"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="967694121" root="1.3.6.1.4.1.519.1"/>
            <name>Padagis US LLC</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="ac128603-d7fe-44ee-90a8-c51b1394b983"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20180808"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0574-7040" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Belladonna and Opium</name>
                        <formCode code="C42993" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUPPOSITORY"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>ATROPA BELLADONNA and OPIUM</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="16.2"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="WQZ3G9PF0H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ATROPA BELLADONNA</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="WQZ3G9PF0H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ATROPA BELLADONNA</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="60"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="37M3MZ001L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OPIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="37M3MZ001L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OPIUM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OJ4Z5Z32L4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 1450</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="CAL22UVI4M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 60</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43199" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKET"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="12"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0574-7040-12" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="19970422"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43199" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKET"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0574-7040-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180822"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <code code="C73627" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Unapproved drug other"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19970422"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38295" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RECTAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0574-7045" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Belladonna and Opium</name>
                        <formCode code="C42993" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUPPOSITORY"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>ATROPA BELLADONNA and OPIUM</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="16.2"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="WQZ3G9PF0H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ATROPA BELLADONNA</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="WQZ3G9PF0H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ATROPA BELLADONNA</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="30"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="37M3MZ001L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OPIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="37M3MZ001L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OPIUM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OJ4Z5Z32L4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 1450</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="CAL22UVI4M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 60</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43199" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKET"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="12"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0574-7045-12" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="19940501"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43199" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKET"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0574-7045-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180822"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <code code="C73627" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Unapproved drug other"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19940501"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38295" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RECTAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_ba1af05a-a2f7-4b07-b70d-dd35ca2ddb77">
               <id root="40d3afae-6f94-4144-a83f-9dd9208f92e0"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20230809"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <paragraph>Dosage and Administration (<linkHtml href="#ID_22863ca8-29bc-4776-a95e-c75e729242b3">2.2</linkHtml>)                          04/2023</paragraph>
                        <paragraph>Warnings and Precautions (<linkHtml href="#ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">5.1</linkHtml>, <linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>, <linkHtml href="#ID_02e110c9-3326-4c0f-a5e5-7c2195a5f913">5.4</linkHtml>)              04/2023</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_2171cd8a-3e7b-4238-aa96-ab06a48a0ad1">
               <id root="adfb714a-f4e8-427f-8a36-0e44f8c47a00"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
               <title>WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Addiction, Abuse, and Misuse</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing belladonna and opium suppositories, and monitor all patients regularly for the development of these behaviors or conditions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">5.1</linkHtml>)]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Life-Threatening Respiratory Depression</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Serious, life-threatening, or fatal respiratory depression may occur with use of belladonna and opium suppositories. Monitor for respiratory depression, especially during initiation of belladonna and opium suppositories or following a dose increase <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>)]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Accidental Exposure</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Accidental exposure of even one dose of belladonna and opium suppositories, especially by children, can result in a fatal overdose of opium <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>)]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Neonatal Opioid Withdrawal Syndrome</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Prolonged use of belladonna and opium suppositories during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_526c295d-321b-4ade-b9b5-c8703c035c30">5.3</linkHtml>)]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_02e110c9-3326-4c0f-a5e5-7c2195a5f913">5.4</linkHtml>), Drug Interactions (<linkHtml href="#ID_a3c6bf78-2b39-4103-bb09-dda73474bf9c">7</linkHtml>)]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">•   Reserve concomitant prescribing of belladonna and opium suppositories and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">•   Limit dosages and durations to the minimum required.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">•   Follow patients for signs and symptoms of respiratory depression and sedation.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230809"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">•   Belladonna and opium suppositories expose users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess patient’s risk before prescribing and monitor regularly for these behaviors or conditions. (<linkHtml href="#ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">5.1</linkHtml>)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">•   Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase. (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">•   Accidental exposure of belladonna and opium suppositories, especially by children, can result in a fatal overdose of opium. (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">•   Prolonged use of belladonna and opium suppositories during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. (<linkHtml href="#ID_526c295d-321b-4ade-b9b5-c8703c035c30">5.3</linkHtml>) </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">•   Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation. (<linkHtml href="#ID_02e110c9-3326-4c0f-a5e5-7c2195a5f913">5.4</linkHtml>, <linkHtml href="#ID_a3c6bf78-2b39-4103-bb09-dda73474bf9c">7</linkHtml>)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_0c2e9501-c895-4e5a-8d27-5b6cce57941b">
               <id root="1be2853f-c65a-472a-9876-b3ee4c80961f"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>Belladonna and opium suppositories are indicated for the management of ureteral spasm pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Limitations of Use</content>
                  </paragraph>
                  <paragraph>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">5.1</linkHtml>)]</content>, reserve belladonna and opium suppositories for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Have not been tolerated, or are not expected to be tolerated,</item>
                     <item>
                        <caption>•</caption>Have not provided adequate analgesia, or are not expected to provide adequate analgesia</item>
                  </list>
               </text>
               <effectiveTime value="20230809"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Belladonna and opium suppositories are an opioid agonist indicated for the management of ureteral spasm pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. (<linkHtml href="#_1_INDICATIONS_AND">1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content> (<linkHtml href="#_1_INDICATIONS_AND">1</linkHtml>)</paragraph>
                        <paragraph>Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve belladonna and opium suppositories for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products):</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Have not been tolerated, or are not expected to be tolerated,</item>
                           <item>
                              <caption>•</caption>Have not provided adequate analgesia, or are not expected to provide adequate analgesia</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_3bcd19cc-6bcc-4102-b47e-878159efd54d">
               <id root="96c74c05-34f4-4243-8213-7cfba9a42053"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20230809"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. (<linkHtml href="#ID_8b97fbdf-b934-4cd3-bf7a-a5a1f00f9801">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Individualize dosing based on the severity of pain, patient response, and prior analgesic experience, and risk factor for addiction, abuse, and misuse. (<linkHtml href="#ID_8b97fbdf-b934-4cd3-bf7a-a5a1f00f9801">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Discuss availability of naloxone with the patient and caregiver and assess each patient's need for access to naloxone, both when initiating and renewing treatment with belladonna and opium suppositories. Consider prescribing naloxone based on the patient's risk factors for overdose. (<linkHtml href="#ID_22863ca8-29bc-4776-a95e-c75e729242b3">2.2</linkHtml>, <linkHtml href="#ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">5.1</linkHtml>, <linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>, <linkHtml href="#ID_02e110c9-3326-4c0f-a5e5-7c2195a5f913">5.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Initiate dosing with one suppository once or twice daily as needed for pain. (<linkHtml href="#ID_e508ec93-1b61-4e5a-9f19-8b7076987665">2.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Do not abruptly discontinue belladonna and opium suppositories in a physically-dependent patient because rapid discontinuation of opioid analgesics has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. (<linkHtml href="#ID_305e78b8-5fdc-4725-9b43-dd633b5fbfab">2.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_8b97fbdf-b934-4cd3-bf7a-a5a1f00f9801">
                     <id root="dd09a0bd-dcc9-45d0-9cb2-1e10c47c38ca"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Dosage and Administration Instructions </title>
                     <text>
                        <paragraph>Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_1c81a704-0f83-4912-8056-7ab1961ba2c6">5</linkHtml>)]</content>.</paragraph>
                        <paragraph>Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">5.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy and following dosage increases with belladonna and opium suppositories and adjust the dosage accordingly <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_22863ca8-29bc-4776-a95e-c75e729242b3">
                     <id root="36d8f5a9-655b-40f7-aa77-cae19753f74a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose  </title>
                     <text>
                        <paragraph>Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with belladonna and opium suppositories <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>), Patient Counseling Information (<linkHtml href="#ID_36724bad-4ec0-4ba5-af87-c2d40fe25d4f">17</linkHtml>)]</content>.</paragraph>
                        <paragraph>Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program).</paragraph>
                        <paragraph>Consider prescribing naloxone, based on the patient's risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">5.1</linkHtml>, <linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>, <linkHtml href="#ID_02e110c9-3326-4c0f-a5e5-7c2195a5f913">5.4</linkHtml>)]</content>.</paragraph>
                        <paragraph>Consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e508ec93-1b61-4e5a-9f19-8b7076987665">
                     <id root="1841f153-db29-422b-be34-8a9adaa52666"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosing </title>
                     <text>
                        <paragraph>One belladonna and opium suppository rectally once or twice daily, not to exceed four doses daily or as recommended by the physician. Moisten finger and suppository with water before inserting. Absorption is dependent on body hydration and not on body temperature.<content styleCode="bold"> Not recommended for use in children 12 years of age and under.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Conversion from Other Opioids to Belladonna and Opium Suppositories</content>
                        </paragraph>
                        <paragraph>There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dosage of belladonna and opium suppositories. It is safer to underestimate a patient’s 24-hour belladonna and opium suppositories dosage than to overestimate the 24-hour belladonna and opium suppositories dosage and manage an adverse reaction due to overdose.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Conversion from Belladonna and Opium suppositories to Extended-Release Opioid</content>
                        </paragraph>
                        <paragraph>The relative bioavailability of belladonna and opium suppositories compared to extended-release opioid is unknown, so conversion to extended-release drug product must be accompanied by close observation for signs of excessive sedation and respiratory depression.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_69eaaa49-5fcc-4790-beeb-cc64b8c4bb30">
                     <id root="1ebd5e1d-7169-4d63-a6c4-9e10103ff445"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Maintenance of Therapy </title>
                     <text>
                        <paragraph>Continually reevaluate patients receiving belladonna and opium suppositories to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">5.1</linkHtml>)]</content>. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.</paragraph>
                        <paragraph>If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the belladonna and opium suppositories dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_305e78b8-5fdc-4725-9b43-dd633b5fbfab">
                     <id root="d2027033-2cd5-4668-b8b3-40373c3b842a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Safe Reduction or Discontinuation of Belladonna and Opium Suppositories </title>
                     <text>
                        <paragraph>Do not abruptly discontinue belladonna and opium suppositories in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.</paragraph>
                        <paragraph>When a decision has been made to decrease the dose or discontinue therapy in an opioid dependent patient taking belladonna and opium suppositories, there are a variety of factors that should be considered, including the dose of belladonna and opium suppositories the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with co-morbid pain and substance use disorders may benefit from referral to a specialist.</paragraph>
                        <paragraph>There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on belladonna and opium suppositories who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper. It may be necessary to provide the patient with lower dosage strengths to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, monitor patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.</paragraph>
                        <paragraph>When managing patients taking opioid analgesics, particularly those who have been treated for a long duration and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_3c7bc8fd-6e46-456d-88f6-177a864e092f">5.12</linkHtml>), Drug Abuse and Dependence (<linkHtml href="#ID_c01015a3-7f57-4956-a851-4f871418e115">9.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_1d761187-603d-415b-b71a-7eb3ca56bb3a">
               <id root="b2d43ee3-9f7d-4115-a921-c82829eab1ed"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Belladonna and Opium Suppositories are available in two strengths.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Belladonna 16.2 mg and opium 30 mg</item>
                     <item>
                        <caption>•</caption>Belladonna 16.2 mg and opium 60 mg</item>
                  </list>
               </text>
               <effectiveTime value="20190501"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Suppositories:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Belladonna 16.2 mg and opium 30 mg</item>
                           <item>
                              <caption>•</caption>Belladonna 16.2 mg and opium 60 mg</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_f54d26a9-c14a-4159-a0e9-dba51873659c">
               <id root="5be50545-411f-462d-9512-d9948e9a915e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>Belladonna and opium suppositories are contraindicated in patients with: </item>
                  </list>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Significant respiratory depression <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_b0f31da0-02c3-423b-bfec-425171e3bdba">5.5</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_0c50ee12-75b5-4cbd-9abd-48b9f5be7bd7">5.6</linkHtml>
                        </content>
                        <content styleCode="italics">), Drug Interactions (<linkHtml href="#ID_a3c6bf78-2b39-4103-bb09-dda73474bf9c">7</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Known or suspected gastrointestinal obstruction, including paralytic ileus <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_23c40b5a-a689-4c1d-9b73-32e23f0d83d8">5.10</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hypersensitivity to opium or belladonna <content styleCode="italics">[see Adverse Events (<linkHtml href="#ID_f9b03188-60fd-4199-8e66-e6cac025c5a6">6</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Glaucoma<sup>2</sup>
                     </item>
                     <item>
                        <caption>•</caption>Severe hepatic or renal disease<sup>2</sup>
                     </item>
                     <item>
                        <caption>•</caption>Narcotic idiosyncrasies<sup>2</sup>
                     </item>
                     <item>
                        <caption>•</caption>Convulsive disorders<sup>2</sup>
                     </item>
                     <item>
                        <caption>•</caption>Acute alcoholism<sup>2</sup>
                     </item>
                     <item>
                        <caption>•</caption>Delirium tremens<sup>2</sup>
                     </item>
                     <item>
                        <caption>•</caption>Premature labor<sup>2</sup>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230809"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Significant respiratory depression. (<linkHtml href="#ID_f54d26a9-c14a-4159-a0e9-dba51873659c">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment. (<linkHtml href="#ID_f54d26a9-c14a-4159-a0e9-dba51873659c">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days. (<linkHtml href="#ID_f54d26a9-c14a-4159-a0e9-dba51873659c">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Known or suspected gastrointestinal obstruction, including paralytic ileus. (<linkHtml href="#ID_f54d26a9-c14a-4159-a0e9-dba51873659c">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Known hypersensitivity to opium or belladonna. (<linkHtml href="#ID_f54d26a9-c14a-4159-a0e9-dba51873659c">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_1c81a704-0f83-4912-8056-7ab1961ba2c6">
               <id root="d16f35de-9f6e-42fa-9654-2b6ef80e3719"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <text>
                  <paragraph>These preparations are not recommended for use in children.</paragraph>
               </text>
               <effectiveTime value="20230809"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients:</content> Monitor closely, particularly during initiation and titration. (<linkHtml href="#ID_b0f31da0-02c3-423b-bfec-425171e3bdba">5.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Adrenal Insufficiency:</content> If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. (<linkHtml href="#ID_babcac95-a6c6-4621-9fe6-1d9141a2eb44">5.7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Severe Hypotension:</content> Monitor during dosage initiation and titration. Avoid use of belladonna and opium suppositories in patients with circulatory shock. (<linkHtml href="#ID_dc409401-57a0-48bc-8138-1e5b8cb8c321">5.8</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness:</content> Monitor for sedation and respiratory depression. Avoid use of belladonna and opium suppositories in patients with impaired consciousness or coma. (<linkHtml href="#ID_7be8479b-6d03-4b56-927d-ad6ed8be6af0">5.9</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">
                     <id root="d15e8682-c4cf-486c-a2c3-fad68d318f10"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Addiction, Abuse, and Misuse  </title>
                     <text>
                        <paragraph>Belladonna and opium suppositories contains opium, a Schedule II controlled substance. As an opioid, belladonna and opium suppositories expose users to the risks of addiction, abuse, and misuse <content styleCode="italics">[see Drug Abuse and Dependence (<linkHtml href="#ID_e656e166-3951-4b94-92a0-249e93d7ad75">9</linkHtml>)]</content>.</paragraph>
                        <paragraph>Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed belladonna and opium suppositories. Addiction can occur at recommended dosages and if the drug is misused or abused.</paragraph>
                        <paragraph>Assess each patient’s risk for opioid addiction, abuse, or misuse prior to prescribing belladonna and opium suppositories, and monitor all patients receiving belladonna and opium suppositories for the development of these behaviors or conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as belladonna and opium suppositories, but use in such patients necessitates intensive counseling about the risks and proper use of belladonna and opium suppositories along with intensive monitoring for signs of addiction, abuse, and misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_22863ca8-29bc-4776-a95e-c75e729242b3">2.2</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_02e110c9-3326-4c0f-a5e5-7c2195a5f913">5.4</linkHtml>)]</content>.</paragraph>
                        <paragraph>Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing belladonna and opium suppositories. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug <content styleCode="italics">[see Patient Counseling Information (<linkHtml href="#ID_36724bad-4ec0-4ba5-af87-c2d40fe25d4f">17</linkHtml>)]</content>. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">
                     <id root="6c998a4a-05b0-47e5-8847-bcc7cb5880ae"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Life-Threatening Respiratory Depression </title>
                     <text>
                        <paragraph>Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient’s clinical status <content styleCode="italics">[see Overdosage (<linkHtml href="#ID_3eca8c2f-06ac-422c-837e-ed1c020daed1">10</linkHtml>)]</content>. Carbon dioxide (CO<sub>2</sub>) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.</paragraph>
                        <paragraph>While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of belladonna and opium suppositories, the risk is greatest during the initiation of therapy or following a dosage increase. Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy with and following dosage increases of belladonna and opium suppositories.</paragraph>
                        <paragraph>To reduce the risk of respiratory depression, proper dosing of belladonna and opium suppositories is essential <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_e508ec93-1b61-4e5a-9f19-8b7076987665">2.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Overestimating the belladonna and opium suppositories dosage when converting patients from another opioid product can result in a fatal overdose with the first dose.</paragraph>
                        <paragraph>Accidental exposure of even one dose of belladonna and opium suppositories, especially by children, can result in respiratory depression and death due to an overdose of opium.</paragraph>
                        <paragraph>Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose <content styleCode="italics">[see Patient Counseling Information (<linkHtml href="#ID_36724bad-4ec0-4ba5-af87-c2d40fe25d4f">17</linkHtml>)]</content>.</paragraph>
                        <paragraph>Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_305e78b8-5fdc-4725-9b43-dd633b5fbfab">2.5</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose</content>
                        </paragraph>
                        <paragraph>Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with belladonna and opium suppositories. Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program). Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help, even if naloxone is administered <content styleCode="italics">[see Patient Counseling Information (<linkHtml href="#ID_36724bad-4ec0-4ba5-af87-c2d40fe25d4f">17</linkHtml>)]</content>.</paragraph>
                        <paragraph>Consider prescribing naloxone, based on the patient's risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient. Also consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose. If naloxone is prescribed, educate patients and caregivers on how to treat with naloxone <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>, <linkHtml href="#ID_0c50ee12-75b5-4cbd-9abd-48b9f5be7bd7">5.6</linkHtml>), Patient Counseling Information (<linkHtml href="#ID_36724bad-4ec0-4ba5-af87-c2d40fe25d4f">17</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_526c295d-321b-4ade-b9b5-c8703c035c30">
                     <id root="26dfc8eb-e29b-45d6-8878-46948d4f1951"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Neonatal Opioid Withdrawal Syndrome </title>
                     <text>
                        <paragraph>Prolonged use of belladonna and opium suppositories during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Advise pregnant women using opioids for a prolonged period of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_744e192d-8fb4-42ed-b9e2-480fb2094902">8.1</linkHtml>), Patient Counseling Information (<linkHtml href="#ID_36724bad-4ec0-4ba5-af87-c2d40fe25d4f">17</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_02e110c9-3326-4c0f-a5e5-7c2195a5f913">
                     <id root="5a2fb478-5d05-4d21-ba34-9628176a4115"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Risks from Concomitant Use with Benzodiazepines or Other Central Nervous System Depressants </title>
                     <text>
                        <paragraph>Profound sedation, respiratory depression, coma, and death may result from the concomitant use of belladonna and opium suppositories with benzodiazepines or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.</paragraph>
                        <paragraph>Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_a3c6bf78-2b39-4103-bb09-dda73474bf9c">7</linkHtml>)]</content>.</paragraph>
                        <paragraph>If the decision is made to prescribe a benzodiazepine or other CNS depressant concomitantly with an opioid analgesic, prescribe the lowest effective dosages and minimum durations of concomitant use. In patients already receiving an opioid analgesic, prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking a benzodiazepine or other CNS depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response. Follow patients closely for signs and symptoms of respiratory depression and sedation.</paragraph>
                        <paragraph>If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_22863ca8-29bc-4776-a95e-c75e729242b3">2.2</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_02e110c9-3326-4c0f-a5e5-7c2195a5f913">5.4</linkHtml>)]</content>.</paragraph>
                        <paragraph>Advise both patients and caregivers about the risks of respiratory depression and sedation when belladonna and opium suppositories are used with benzodiazepines or other CNS depressants (including alcohol and illicit drugs). Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined. Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_a3c6bf78-2b39-4103-bb09-dda73474bf9c">7</linkHtml>) and Patient Counseling Information (<linkHtml href="#ID_36724bad-4ec0-4ba5-af87-c2d40fe25d4f">17</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b0f31da0-02c3-423b-bfec-425171e3bdba">
                     <id root="dd22433f-7c13-4bfe-9c1d-f81afc61be27"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients </title>
                     <text>
                        <paragraph>The use of belladonna and opium suppositories in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Patients with Chronic Pulmonary Disease</content>: Belladonna and opium suppositories-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of belladonna and opium suppositories <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elderly, Cachetic, or Debilitated Patients</content>: Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>Monitor such patients closely, particularly when initiating and titrating belladonna and opium suppositories and when belladonna and opium suppositories is given concomitantly with other drugs that depress respiration <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>)]</content>. Alternatively, consider the use of non-opioid analgesics in these patients.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0c50ee12-75b5-4cbd-9abd-48b9f5be7bd7">
                     <id root="ef8328e0-4895-4209-ba22-5f18cfb61cf0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Interactions with Monoamine Oxidase Inhibitors </title>
                     <text>
                        <paragraph>Monoamine oxidase inhibitors (MAOIs) may potentiate the effects of opioids, including respiratory depression, coma, and confusion. Belladonna and opium suppositories should not be used in patients taking MAOIs or within 14 days of stopping such treatment.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_babcac95-a6c6-4621-9fe6-1d9141a2eb44">
                     <id root="74746dad-2773-419b-b4fd-dbc2534a4f9b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Adrenal Insufficiency </title>
                     <text>
                        <paragraph>Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.</paragraph>
                     </text>
                     <effectiveTime value="20180808"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_dc409401-57a0-48bc-8138-1e5b8cb8c321">
                     <id root="c2377880-70a8-4f03-b62f-5651434f1192"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Severe Hypotension </title>
                     <text>
                        <paragraph>Belladonna and opium suppositories may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) <content styleCode="italics">[see Drug Interactions (7)]</content>. Monitor these patients for signs of hypotension after initiating or titrating the dosage of belladonna and opium suppositories. In patients with circulatory shock, belladonna and opium suppositories may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of belladonna and opium suppositories in patients with circulatory shock.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7be8479b-6d03-4b56-927d-ad6ed8be6af0">
                     <id root="822c947c-eaee-4aa7-a60a-563d04c41372"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness </title>
                     <text>
                        <paragraph>In patients who may be susceptible to the intracranial effects of CO<sub>2</sub> retention (e.g., those with evidence of increased intracranial pressure or brain tumors), belladonna and opium suppositories may reduce respiratory drive, and the resultant CO<sub>2</sub> retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with belladonna and opium suppositories.</paragraph>
                        <paragraph>Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of belladonna and opium suppositories in patients with impaired consciousness or coma.</paragraph>
                     </text>
                     <effectiveTime value="20180808"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_23c40b5a-a689-4c1d-9b73-32e23f0d83d8">
                     <id root="b2a9763a-1606-4e05-b490-db91e61dab9d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Risks of Use in Patients with Gastrointestinal Conditions </title>
                     <text>
                        <paragraph>Belladonna and opium suppositories are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.</paragraph>
                        <paragraph>The opium in belladonna and opium suppositories may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20180808"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_937e0fab-87a3-492b-8546-cf84ccc89f47">
                     <id root="aef49c0a-66fb-4d33-a78e-f17eba47a692"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Increased Risk of Seizures in Patients with Seizure Disorders </title>
                     <text>
                        <paragraph>The opium in belladonna and opium suppositories may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control during belladonna and opium suppositories therapy.</paragraph>
                     </text>
                     <effectiveTime value="20180808"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3c7bc8fd-6e46-456d-88f6-177a864e092f">
                     <id root="3225566f-e772-4b9b-9116-e9c1c312ca45"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Withdrawal </title>
                     <text>
                        <paragraph>Do not abruptly discontinue belladonna and opium suppositories in a patient physically dependent on opioids. When discontinuing belladonna and opium suppositories in a physically dependent patient, gradually taper the dosage. Rapid tapering of opium in a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_305e78b8-5fdc-4725-9b43-dd633b5fbfab">2.5</linkHtml>), Drug Abuse and Dependence (<linkHtml href="#ID_c01015a3-7f57-4956-a851-4f871418e115">9.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including belladonna and opium suppositories. In these patients, mixed agonist/antagonist and partial agonist analgesics may reduce the analgesic effect and/or precipitate withdrawal symptoms <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_a3c6bf78-2b39-4103-bb09-dda73474bf9c">7</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_bfe459da-96c5-45bd-8e4d-a0c91a7cccba">
                     <id root="77d98e7e-4788-4271-8de3-791badc49c22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13 Risks of Driving and Operating Machinery </title>
                     <text>
                        <paragraph>Belladonna and opium suppositories may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of belladonna and opium suppositories and know how they will react to the medication.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f9b03188-60fd-4199-8e66-e6cac025c5a6">
               <id root="13bf061d-7181-4f73-8595-e9a2e6e4892e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>Belladonna may cause drowsiness, dry mouth, urinary retention, photophobia, rapid pulse, dizziness and blurred vision<sup>7</sup>. Opium usage may result in constipation, nausea or vomiting. Pruritis and urticaria may occasionally occur. Hypersensitivity to opium or belladonna may occur.</paragraph>
                  <paragraph>The following serious adverse reactions are described, or described in greater detail, in other sections:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Addiction, Abuse, and Misuse <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">5.1</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Life-Threatening Respiratory Depression <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Neonatal Opioid Withdrawal Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_526c295d-321b-4ade-b9b5-c8703c035c30">5.3</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Interactions with Benzodiazepines and Other CNS Depressants <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_02e110c9-3326-4c0f-a5e5-7c2195a5f913">5.4</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Adrenal Insufficiency <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_babcac95-a6c6-4621-9fe6-1d9141a2eb44">5.7</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Severe Hypotension <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_dc409401-57a0-48bc-8138-1e5b8cb8c321">5.8</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Gastrointestinal Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_23c40b5a-a689-4c1d-9b73-32e23f0d83d8">5.10</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Seizures <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_937e0fab-87a3-492b-8546-cf84ccc89f47">5.11</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Withdrawal <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_3c7bc8fd-6e46-456d-88f6-177a864e092f">5.12</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230809"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions are drowsiness, dry mouth, urinary retention, photophobia, rapid pulse, dizziness and blurred vision, constipation, nausea and vomiting. (<linkHtml href="#ID_f9b03188-60fd-4199-8e66-e6cac025c5a6">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Padagis<sup>®</sup>
                           </content>
                           <content styleCode="bold"> at 1-866-634-9120 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_1f09e000-601f-41cd-9900-5f0555ddcb1c">
                     <id root="b7febf00-601a-4afe-993c-bc478547df0f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of opioids. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Serotonin syndrome: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs. </paragraph>
                        <paragraph>Adrenal insufficiency: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. </paragraph>
                        <paragraph>Anaphylaxis: Anaphylaxis has been reported with products containing opioids.</paragraph>
                        <paragraph>Androgen deficiency: Cases of androgen deficiency have occurred with chronic use of opioids. </paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a3c6bf78-2b39-4103-bb09-dda73474bf9c">
               <id root="e01999d9-ac55-4eb3-b2cd-6af1d15dc2c0"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <text>
                  <paragraph>Table 1 includes clinically significant drug interactions with belladonna and opium suppositories. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 1: Clinically Significant Drug Interactions with Belladonna and Opium Suppositories</content>
                  </paragraph>
                  <table width="100%">
                     <col width="20%"/>
                     <col width="79%"/>
                     <tbody>
                        <tr>
                           <td colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation. If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_22863ca8-29bc-4776-a95e-c75e729242b3">2.2</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">5.1</linkHtml>, <linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>, <linkHtml href="#ID_02e110c9-3326-4c0f-a5e5-7c2195a5f913">5.4</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Examples:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Serotonergic Drugs</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue belladonna and opium suppositories if serotonin syndrome is suspected.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Examples:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>)]</content>
                              </paragraph>
                              <paragraph>If urgent use of an opioid is necessary, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>The use of belladonna and opium suppositories is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Examples:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>phenelzine, tranylcypromine, linezolid</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>May reduce the analgesic effect of belladonna and opium suppositories and/or precipitate withdrawal symptoms.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Avoid concomitant use.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Examples:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>butorphanol, nalbuphine, pentazocine, buprenorphine</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Muscle Relaxants</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Opium may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of belladonna and opium suppositories and/or the muscle relaxant as necessary. Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_22863ca8-29bc-4776-a95e-c75e729242b3">2.2</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>, <linkHtml href="#ID_02e110c9-3326-4c0f-a5e5-7c2195a5f913">5.4</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Diuretics</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Anticholinergic Drugs</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>Monitor patients for signs of urinary retention or reduced gastric motility when belladonna and opium suppositories are used concomitantly with anticholinergic drugs.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20230809"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Serotonergic Drugs:</content> Concomitant use may result in serotonin syndrome. Discontinue belladonna and opium suppositories if serotonin syndrome is suspected. (<linkHtml href="#ID_a3c6bf78-2b39-4103-bb09-dda73474bf9c">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Monoamine Oxidase Inhibitors (MAOIs):</content> Can potentiate the effects of opium. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping treatment with an MAOI. (<linkHtml href="#ID_a3c6bf78-2b39-4103-bb09-dda73474bf9c">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics:</content> Avoid use with belladonna and opium suppositories because they may reduce analgesic effect of belladonna and opium suppositories or precipitate withdrawal symptoms. (<linkHtml href="#ID_a3c6bf78-2b39-4103-bb09-dda73474bf9c">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_effc5526-4d11-4b5e-817f-6c1f3082e5cd">
               <id root="5f1cad93-e86a-4937-98eb-b8f6dc7029f2"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20230809"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>: May cause fetal harm. (<linkHtml href="#ID_744e192d-8fb4-42ed-b9e2-480fb2094902">8.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_744e192d-8fb4-42ed-b9e2-480fb2094902">
                     <id root="e960431a-c677-4b91-b3ba-ba73cd841466"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome. There are no available data with belladonna and opium suppositories in pregnant women to inform a drug associated risk for major birth defects and miscarriage.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth.</paragraph>
                        <paragraph>Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_526c295d-321b-4ade-b9b5-c8703c035c30">5.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>Belladonna refers to plant alkaloids that contain anticholinergic agents such as atropine. Atropine used in human pregnancies has not been associated with birth defects or adverse fetal effects although the drug readily crosses the placenta. Use during pregnancy may increase risk of respiratory abnormalities, hypospadias, and eye or ear malformations but causal relationship is unclear. The Collaborative Perinatal Project found no relationship between first trimester use of atropine and birth defects in the offspring but found an increase in birth defects in general in the offspring of pregnancies where the mother had taken belladonna. There was no relationship to any particular syndrome of anomalies. A statistically significant (although weak) association was discovered between congenital anomalies and maternal use of belladonna. A study was conducted based on the infants of 554 women who took belladonna during the first four months of pregnancy. The study was conducted in the Collaborative Perinatal Project and showed that belladonna is unlikely to cause minor congenital abnormalities. The estimated maximum risk is most likely less than 3% if maternal belladonna is used early in pregnancy.<sup>1</sup>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Labor or Delivery</content>
                        </paragraph>
                        <paragraph>Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. Belladonna and opium suppositories is not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. Opioid analgesics, including belladonna and opium suppositories, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_95b37568-59fa-4066-8920-59b757c14ec8">
                     <id root="795b5203-f5a9-4474-9437-63a72b4f4655"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for belladonna and opium suppositories and any potential adverse effects on the breastfed infant from belladonna and opium suppositories or from the underlying maternal condition.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>Infants exposed to belladonna and opium suppositories through breast milk should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped.</paragraph>
                     </text>
                     <effectiveTime value="20180808"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8ddc4b6a-6501-4555-9363-b1f62b225ab5">
                     <id root="aca5a607-d668-4949-b005-d92b60b84e34"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential </title>
                     <text>
                        <paragraph>Infertility</paragraph>
                        <paragraph>Chronic use of opioids may cause reduced fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3eb73dd2-ac47-402b-974e-61b42b24f9e1">
                     <id root="822a31d2-c1bb-45c4-8f70-2d8807804b6e"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and effectiveness of belladonna and opium suppositories in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20180808"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a72516f5-cb78-4b5e-b0e6-d6061ea891b5">
                     <id root="3e9181e9-b613-4668-9d2a-e87dab290f52"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Elderly patients (aged 65 years or older) may have increased sensitivity to belladonna and opium. In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>Respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of belladonna and opium suppositories slowly in geriatric patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e656e166-3951-4b94-92a0-249e93d7ad75">
               <id root="ca280a8b-f7ed-4f2a-a2da-cd5709ac8e35"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE </title>
               <effectiveTime value="20230809"/>
               <component>
                  <section ID="ID_43a7d275-7a9c-47c6-8e4e-54c02ec92fb4">
                     <id root="89b1a5a7-6ca6-4149-af37-9ec36aa9bd2e"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance </title>
                     <text>
                        <paragraph>Belladonna and opium suppositories contains opium, a Schedule II controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20180808"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_247aa874-0308-466d-972f-b634da362c06">
                     <id root="1aed891f-a6ed-4da6-ac8d-6b1f370690b7"/>
                     <code code="34086-9" codeSystem="2.16.840.1.113883.6.1" displayName="ABUSE SECTION"/>
                     <title>9.2 Abuse </title>
                     <text>
                        <paragraph>Belladonna and opium suppositories contains opium, a substance with a high potential for abuse similar to other opioids including fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tapentadol. Belladonna and opium suppositories can be abused and is subject to misuse, addiction, and criminal diversion <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">5.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>All patients treated with opioids require careful monitoring for signs of abuse and addiction, since use of opioid analgesic products carries the risk of addiction even under appropriate medical use.</paragraph>
                        <paragraph>Prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects.</paragraph>
                        <paragraph>Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and includes: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal.</paragraph>
                        <paragraph>“Drug-seeking” behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating health care provider(s). “Doctor shopping” (visiting multiple prescribers) to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control.</paragraph>
                        <paragraph>Abuse and addiction are separate and distinct from physical dependence and tolerance. Health care providers should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction.</paragraph>
                        <paragraph>Belladonna and opium suppositories, like other opioids, can be diverted for non-medical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.</paragraph>
                        <paragraph>Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risks Specific to Abuse of Belladonna and Opium Suppositories</content>
                        </paragraph>
                        <paragraph>Belladonna and opium suppositories are for rectal use only. Abuse of belladonna and opium suppositories poses a risk of overdose and death. The risk is increased with concurrent abuse of belladonna and opium suppositories with alcohol and other central nervous system depressants. </paragraph>
                        <paragraph>Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c01015a3-7f57-4956-a851-4f871418e115">
                     <id root="687f7303-915a-4d7c-9494-327f7a10c625"/>
                     <code code="34087-7" codeSystem="2.16.840.1.113883.6.1" displayName="DEPENDENCE SECTION"/>
                     <title>9.3 Dependence </title>
                     <text>
                        <paragraph>Both tolerance and physical dependence can develop during chronic opioid therapy. Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects.</paragraph>
                        <paragraph>Physical dependence results in withdrawal symptoms after abrupt discontinuation or a significant dosage reduction of a drug. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene), mixed agonist/antagonist analgesics (pentazocine, butorphanol, nalbuphine), or partial agonists (buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage.</paragraph>
                        <paragraph>Belladonna and opium suppositories should not be abruptly discontinued <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_305e78b8-5fdc-4725-9b43-dd633b5fbfab">2.4</linkHtml>)]</content>. If belladonna and opium suppositories is abruptly discontinued in a physically-dependent patient, a withdrawal syndrome may occur. Some or all of the following can characterize this syndrome: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.</paragraph>
                        <paragraph>Do not abruptly discontinue belladonna and opium suppositories in a patient physically dependent on opioids. Rapid tapering of belladonna and opium suppositories in a patient physically dependent on opioids may lead to serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. </paragraph>
                        <paragraph>When discontinuing belladonna and opium suppositories, gradually taper the dosage using a patient-specific plan that considers the following: the dose of belladonna and opium suppositories the patient has been taking, the duration of treatment, and the physical and psychological attributes of the patient. To improve the likelihood of a successful taper and minimize withdrawal symptoms, it is important that the opioid tapering schedule is agreed upon by the patient. In patients taking opioids for a long duration at high doses, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_305e78b8-5fdc-4725-9b43-dd633b5fbfab">2.5</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_3c7bc8fd-6e46-456d-88f6-177a864e092f">5.12</linkHtml>)]</content>.</paragraph>
                        <paragraph>Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_744e192d-8fb4-42ed-b9e2-480fb2094902">8.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230809"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3eca8c2f-06ac-422c-837e-ed1c020daed1">
               <id root="85300bd4-2cca-459c-9744-c1985262d3d7"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Clinical Presentation</content>
                  </paragraph>
                  <paragraph>Acute overdose with belladonna and opium suppositories can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_60a7b0ac-77b5-446b-a893-e9b90520bb38">12</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Treatment of Overdose</content>
                  </paragraph>
                  <paragraph>In case of overdose, priorities are the reestablishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support techniques.</paragraph>
                  <paragraph>Opioid antagonists, such as naloxone or nalmefene, are specific antidotes to respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to opium overdose, administer an opioid antagonist. </paragraph>
                  <paragraph>Because the duration of opioid reversal is expected to be less than the duration of action of opium in belladonna and opium suppositories, carefully monitor the patient until spontaneous respiration is reliably re-established. If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product’s prescribing information.</paragraph>
                  <paragraph>In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be initiated with care and by titration with smaller than usual doses of the antagonist.</paragraph>
               </text>
               <effectiveTime value="20230809"/>
            </section>
         </component>
         <component>
            <section ID="ID_7da77806-a749-4751-ae88-00c917142796">
               <id root="46b3cdd5-1cc2-47d8-bcc5-1a43efda739d"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Each belladonna and opium suppository contains (in a water-soluble base consisting of polyethylene glycol 400, 1450, 8000 and polysorbate 60):</paragraph>
                  <paragraph>
                     <content styleCode="bold">Belladonna (16.2 mg) and Opium (30 mg):</content>
                  </paragraph>
                  <paragraph>Powdered belladonna extract 16.2 mg and powdered opium 30 mg.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Belladonna (16.2 mg) and Opium (60 mg):</content>
                  </paragraph>
                  <paragraph>Powdered belladonna extract 16.2 mg and powdered opium 60 mg.</paragraph>
                  <paragraph>This drug falls into the pharmacological/therapeutic class of narcotic analgesic/antispasmotic agents.</paragraph>
                  <paragraph>The pharmacologically active principles present in the belladonna extract component of belladonna and opium suppositories are:</paragraph>
                  <renderMultiMedia ID="id302517355" referencedObject="ID_91d5fab7-ad73-46e7-bd87-30fc0efd3239"/>
                  <paragraph>
                     <content styleCode="bold">Established Name:</content> Atropine</paragraph>
                  <paragraph>
                     <content styleCode="bold">Chemical Name:</content> dl Tropyl Tropate</paragraph>
                  <renderMultiMedia ID="id836969215" referencedObject="ID_33a44e0f-74b6-4070-ac0c-7b81839f8260"/>
                  <paragraph>
                     <content styleCode="bold">Established Name:</content> Scopolamine</paragraph>
                  <paragraph>
                     <content styleCode="bold">Chemical Name:</content> dl Scopolamine</paragraph>
                  <paragraph>Opium contains more than twenty alkaloids, the principle ones being morphine (10%), narcotine (6%), papaverine (1%) and codeine (0.5%). The major pharmacologically active principle of the powdered opium component of belladonna and opium suppositories, however, is:</paragraph>
                  <renderMultiMedia ID="id-1816248038" referencedObject="ID_268ca7b9-0f9f-43dc-ad34-5e6c3496f062"/>
                  <paragraph>
                     <content styleCode="bold">Name:</content> Morphine</paragraph>
                  <paragraph>
                     <content styleCode="bold">Chemical Name:</content> 7, 8-Didehydro-4, 5-epoxy-17-Methyl-morphinan-3, 6-diol</paragraph>
               </text>
               <effectiveTime value="20230809"/>
               <component>
                  <observationMedia ID="ID_91d5fab7-ad73-46e7-bd87-30fc0efd3239">
                     <text>table 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_33a44e0f-74b6-4070-ac0c-7b81839f8260">
                     <text>table 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_268ca7b9-0f9f-43dc-ad34-5e6c3496f062">
                     <text>table 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_60a7b0ac-77b5-446b-a893-e9b90520bb38">
               <id root="260263bd-22e1-404e-a9f9-dd9d78dc9396"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20180808"/>
               <component>
                  <section ID="ID_1b1d85fd-62cc-4ec3-b235-acac4a9529b8">
                     <id root="138f9f36-881c-415a-882e-82f11e3e4cc3"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Belladonna/opium rectal suppository is a combination narcotic analgesic/antispasmodic agent. The belladonna extract component of the rectal suppository provides the active alkaloids atropine and scopolamine, while the opium component provides primarily morphine (among more than 20 alkaloids). The atropine alkaloid is parasympatholytic, exerting antispasmodic activity by relaxation of smooth muscle that is stimulated by the parasympathetic nervous system. The atropine alkaloid is also the dl isomer of l-hyoscyamine and exerts the same pharmacologic activity; however, it exerts about one-half the activity peripherally as l-hyoscyamine. Atropine activity also counteracts morphine induced smooth muscle spasm without affecting the analgesia. The morphine alkaloid of opium exerts analgesic activity by increasing the pain threshold and decreasing the sensitivity to pain. The oxidative dealkylated nor-metabolites of morphine begin the analgesic process. Additionally, the side effect of euphoria may contribute to sense of pain relief.</paragraph>
                     </text>
                     <effectiveTime value="20180808"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_236821fb-a700-4581-ae8f-f6549d672e30">
                     <id root="f478c1fd-b76f-4752-93ee-b7410b8db9eb"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>Through its parasympatholytic action, atropine (belladonna) relaxes smooth muscle resulting from parasympathetic stimulation. It is the dl isomer of l-hyoscyamine and therefore exhibits the same clinical effects. It is, however, approximately one-half as active peripherally as l-hyoscyamine, the latter being the major active plant alkaloid. The dl isomer atropine is formed during the process of isolation of the belladonna extract.<sup>1</sup>
                        </paragraph>
                        <paragraph>Morphine, the major active principle of powdered opium, is responsible for the action of powdered opium although the other alkaloids present also contribute to it. The sedative and analgesic action of morphine, the effect desired by inclusion in belladonna and opium suppositories of powdered opium, are thought to be due to the depressant effect on the cerebral cortex, hypothalamus and medullary centers. In large doses, the opiates and their analogs also exhibit synaptic conduction in the spinothalamic tracts, depress the function of the reticular formation, the lemniscus and the thalamic relays, and inhibit spinal synaptic reflexes: but these inhibitor actions should not be elicited with therapeutic doses of the drug. Moderate doses of powdered opium should not alter the electroencephalogram.</paragraph>
                        <paragraph>The action of morphine consists mainly of a descending depression of the central nervous system. It exerts its analgesic action by increasing the pain threshold or the magnitude of stimulus required to evoke pain and by dulling the sensibility or reaction to pain. In addition to its action in abolishing pain, morphine induces a sense of well-being (euphoria) facilitating certain mental processes while retarding others. </paragraph>
                     </text>
                     <effectiveTime value="20180808"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9d2c375a-fd1d-4d50-ab9a-3242c8ae6388">
                     <id root="d970a21f-d601-4e5b-9857-ec34178ff0cb"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>Upon absorption of morphine, oxidative dealkylation to produce nor-compounds appears to be the first step in the reaction sequence which imparts analgesia. Morphine is conjugated in the liver to form the 3-glucuronide which passes into the bile and is reabsorbed and excreted in the urine. The atropine effect of the belladonna extract serves to eliminate morphine induced smooth muscle spasm without affecting the sedative analgesic action of powdered opium.<sup>1</sup>
                        </paragraph>
                     </text>
                     <effectiveTime value="20180808"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9bac12d6-d1dc-4e38-a236-3ecf3db64c2f">
               <id root="a84dded6-e2e3-426e-b57b-378bd24c2f4e"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES </title>
               <text>
                  <paragraph>1. Belladonna. DrugPoints Summary. Micromedex 2.0. Truven Health Analytics, Inc. Greenwood Village, CO. Accessed October 2, 2017. </paragraph>
                  <paragraph>2. Olin BR. Drug Facts and Comparisons, 50th ed. Facts and Comparisons, St Louis, MO; 1999.</paragraph>
               </text>
               <effectiveTime value="20230809"/>
            </section>
         </component>
         <component>
            <section ID="ID_d59b533d-ae0d-484b-8117-775c23e168bf">
               <id root="cd22b872-8924-42e4-8d98-8998137a9589"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>Belladonna (16.2 mg) and Opium (30 mg) suppositories are brown, bullet shaped suppositories. <br/>NDC 0574-7045-04: Carton of 4 suppositories<br/>NDC 0574-7045-12: Carton of 12 suppositories</paragraph>
                  <paragraph>Belladonna (16.2 mg) and Opium (60 mg) suppositories are brown, bullet shaped suppositories.<br/>NDC 0574-7040-04: Carton of 4 suppositories <br/>NDC 0574-7040-12: Carton of 12 suppositories</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. DO NOT REFRIGERATE. PROTECT FROM MOISTURE DURING STORAGE.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
               </text>
               <effectiveTime value="20180808"/>
            </section>
         </component>
         <component>
            <section ID="ID_36724bad-4ec0-4ba5-af87-c2d40fe25d4f">
               <id root="42bbc8ce-6f63-4cb9-b64c-d340bebd2d47"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Advise the patient to read the patient labeling (Medication Guide).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Storage and Disposal</content>
                  </paragraph>
                  <paragraph>Because of the risks associated with accidental ingestion, misuse, and abuse, advise patients to store belladonna and opium suppositories securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">5.1</linkHtml>, <linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>), Drug Abuse and Dependence (<linkHtml href="#ID_247aa874-0308-466d-972f-b634da362c06">9.2</linkHtml>)]</content>. Inform patients that leaving belladonna and opium suppositories unsecured can pose a deadly risk to others in the home.</paragraph>
                  <paragraph>Advise patients and caregivers that when medicines are no longer needed, they should be disposed of promptly. Expired, unwanted, or unused belladonna and opium suppositories should be disposed of by flushing the unused medication down the toilet if a drug take-back option is not readily available. Inform patients that they can visit www.fda.gov/drugdisposal for a complete list of medicines recommended for disposal by flushing, as well as additional information on disposal of unused medicines.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Addiction, Abuse, and Misuse</content>
                  </paragraph>
                  <paragraph>Inform patients that the use of belladonna and opium suppositories, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">5.1</linkHtml>)]</content>. Instruct patients not to share belladonna and opium suppositories with others and to take steps to protect belladonna and opium suppositories from theft or misuse.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Life-Threatening Respiratory Depression</content>
                  </paragraph>
                  <paragraph>Inform patients of the risk of life-threatening respiratory depression, including information that the risk is greatest when starting belladonna and opium suppositories or when the dosage is increased, and that it can occur even at recommended dosages. </paragraph>
                  <paragraph>Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose</content>
                  </paragraph>
                  <paragraph>Discuss with the patient and caregiver the availability of naloxone for the emergency treatment of opioid overdose, both when initiating and renewing treatment with belladonna and opium suppositories. Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_22863ca8-29bc-4776-a95e-c75e729242b3">2.2</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_24e2ed44-c250-4b1b-bab1-9fed09b64f5c">5.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>Educate patients and caregivers on how to recognize the signs and symptoms of an overdose. Explain to patients and caregivers that naloxone's effects are temporary, and that they must call 911 or get emergency medical help right away in all cases of known or suspected opioid overdose, even if naloxone is administered <content styleCode="italics">[see Overdosage (<linkHtml href="#ID_3eca8c2f-06ac-422c-837e-ed1c020daed1">10</linkHtml>)]</content>.</paragraph>
                  <paragraph>If naloxone is prescribed, also advise patients and caregivers:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>How to treat with naloxone in the event of an opioid overdose</item>
                           <item>
                              <caption>•</caption>To tell family and friends about their naloxone and to keep it in a place where family and friends can access it in an emergency</item>
                           <item>
                              <caption>•</caption>To read the Patient Information (or other educational material) that will come with their naloxone. Emphasize the importance of doing this before an opioid emergency happens, so the patient and caregiver will know what to do.</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Accidental Exposure</content>
                  </paragraph>
                  <paragraph>Inform patients that accidental exposure (including ingestion), especially by children, may result in respiratory depression or death <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7624fe9d-27d6-47b9-a9a8-87539bdeb026">5.2</linkHtml>)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Interactions with Benzodiazepines and Other CNS Depressants</content>
                  </paragraph>
                  <paragraph>Inform patients and caregivers that potentially fatal additive effects may occur if belladonna and opium suppositories are used with benzodiazepines or other CNS depressants, including alcohol, and not to use these concomitantly unless supervised by a healthcare provider <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_02e110c9-3326-4c0f-a5e5-7c2195a5f913">5.4</linkHtml>), Drug Interactions (<linkHtml href="#ID_a3c6bf78-2b39-4103-bb09-dda73474bf9c">7</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Serotonin Syndrome</content>
                  </paragraph>
                  <paragraph>Inform patients that belladonna and opium suppositories could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop. Instruct patients to inform their healthcare providers if they are taking, or plan to take serotonergic medications <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_a3c6bf78-2b39-4103-bb09-dda73474bf9c">7</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">MAOI Interaction</content>
                  </paragraph>
                  <paragraph>Inform patients to avoid taking belladonna and opium suppositories while using any drugs that inhibit monoamine oxidase. Patients should not start MAOIs while taking belladonna and opium suppositories <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_a3c6bf78-2b39-4103-bb09-dda73474bf9c">7</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Adrenal Insufficiency</content>
                  </paragraph>
                  <paragraph>Inform patients that belladonna and opium suppositories could cause adrenal insufficiency, a potentially life-threatening condition. Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. Advise patients to seek medical attention if they experience a constellation of these symptoms <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#ID_babcac95-a6c6-4621-9fe6-1d9141a2eb44">5.7</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Important Administration Instructions</content>
                  </paragraph>
                  <paragraph>Instruct patients how to properly take belladonna and opium suppositories.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Advise patients not to adjust the dose of belladonna and opium suppositories without consulting with a physician or other healthcare professional.</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Important Discontinuation Instructions</content>
                  </paragraph>
                  <paragraph>In order to avoid developing withdrawal symptoms, instruct patients not to discontinue belladonna and opium suppositories without first discussing a tapering plan with the prescriber <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_305e78b8-5fdc-4725-9b43-dd633b5fbfab">2.5</linkHtml>)</content>].</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypotension</content>
                  </paragraph>
                  <paragraph>Inform patients that belladonna and opium suppositories may cause orthostatic hypotension and syncope. Instruct patients how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_dc409401-57a0-48bc-8138-1e5b8cb8c321">5.8</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Anaphylaxis</content>
                  </paragraph>
                  <paragraph>Inform patients that anaphylaxis has been reported with ingredients contained in belladonna and opium suppositories. Advise patients how to recognize such a reaction and when to seek medical attention <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_f54d26a9-c14a-4159-a0e9-dba51873659c">4</linkHtml>), Adverse Reactions (<linkHtml href="#ID_f9b03188-60fd-4199-8e66-e6cac025c5a6">6</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Neonatal Opioid Withdrawal Syndrome</content>
                  </paragraph>
                  <paragraph>Inform female patients of reproductive potential that prolonged use of belladonna and opium suppositories during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_526c295d-321b-4ade-b9b5-c8703c035c30">5.3</linkHtml>), Use in Specific Populations (<linkHtml href="#ID_744e192d-8fb4-42ed-b9e2-480fb2094902">8.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Inform female patients of reproductive potential that belladonna and opium suppositories can cause fetal harm and to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_526c295d-321b-4ade-b9b5-c8703c035c30">5.3</linkHtml>), Use in Specific Populations (<linkHtml href="#ID_744e192d-8fb4-42ed-b9e2-480fb2094902">8.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise nursing mothers to monitor infants for increased sleepiness (more than usual), breathing difficulties, or limpness. Instruct nursing mothers to seek immediate medical care if they notice these signs <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_95b37568-59fa-4066-8920-59b757c14ec8">8.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Infertility</content>
                  </paragraph>
                  <paragraph>Inform patients that chronic use of opioids may cause reduced fertility. It is not known whether these effects on fertility are reversible <content styleCode="italics">[see Use in Specific Population (<linkHtml href="#ID_8ddc4b6a-6501-4555-9363-b1f62b225ab5">8.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Driving or Operating Heavy Machinery</content>
                  </paragraph>
                  <paragraph>Inform patients that belladonna and opium suppositories may impair the ability to perform potentially hazardous activities such as driving a car or operating heavy machinery. Advise patients not to perform such tasks until they know how they will react to the medication <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_bfe459da-96c5-45bd-8e4d-a0c91a7cccba">5.13</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Constipation</content>
                  </paragraph>
                  <paragraph>Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_f9b03188-60fd-4199-8e66-e6cac025c5a6">6</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID_60a7b0ac-77b5-446b-a893-e9b90520bb38">12</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <br/>Dispense with Medication Guide available at: www.padagis.com/medguide/BLOPB.</paragraph>
                  <paragraph>
                     <br/>Manufactured by Padagis<sup>®</sup>
                  </paragraph>
                  <paragraph>Minneapolis, MN 55427</paragraph>
                  <paragraph>www.padagis.com</paragraph>
                  <paragraph>Rev 04-23</paragraph>
                  <paragraph>4D800 RC PH4</paragraph>
                  <paragraph>2204541</paragraph>
               </text>
               <effectiveTime value="20230809"/>
            </section>
         </component>
         <component>
            <section ID="ID_06bcacf2-ea42-4baf-a667-a82012511060">
               <id root="ca3d06b3-12fb-40be-86e7-98535b1ad9f6"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>Medication Guide </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Medication Guide</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Belladonna</content> (bell ah DON ah) <content styleCode="bold">and Opium</content> (OH pee um) <content styleCode="bold">Suppositories, CII</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Belladonna and opium suppositories are:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage ureteral spasm pain severe enough to require an opioid analgesic, when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them. </item>
                     <item>
                        <caption>•</caption>An opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Important information about belladonna and opium suppositories:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Get emergency help or call 911 right away if you take too much belladonna and opium suppositories (overdose).</content> When you first start taking belladonna and opium suppositories, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose.</item>
                     <item>
                        <caption>•</caption>Taking belladonna and opium suppositories with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.</item>
                     <item>
                        <caption>•</caption>Never give anyone else your belladonna and opium suppositories. They could die from taking them. Selling or giving away belladonna and opium suppositories is against the law.</item>
                     <item>
                        <caption>•</caption>Store belladonna and opium suppositories securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Do not take belladonna and opium suppositories if you have:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>severe asthma, trouble breathing, or other lung problems. </item>
                     <item>
                        <caption>•</caption>a bowel blockage or have narrowing of the stomach or intestines. </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Before taking belladonna and opium suppositories, tell your healthcare provider if you have a history of:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>head injury, seizures</item>
                     <item>
                        <caption>•</caption>liver, kidney, thyroid problems </item>
                     <item>
                        <caption>•</caption>problems urinating </item>
                     <item>
                        <caption>•</caption>pancreas or gallbladder problems </item>
                     <item>
                        <caption>•</caption>abuse of street or prescription drugs, alcohol addiction, opioid overdose, or mental health problems.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider if you are:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">pregnant or planning to become pregnant.</content> Prolonged use of belladonna and opium suppositories during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.<content styleCode="bold"/>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">breastfeeding.</content> Opium passes into breastmilk and may harm your baby. </item>
                     <item>
                        <caption>•</caption>living in a household where there are small children or someone who has abused street or prescription drugs.</item>
                     <item>
                        <caption>•</caption>taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking belladonna and opium suppositories with certain other medicines can cause serious side effects that could lead to death.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">When taking belladonna and opium suppositories:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Do not change your dose. Take belladonna and opium suppositories exactly as prescribed by your healthcare provider.  Use the lowest dose possible for the shortest time needed. </item>
                     <item>
                        <caption>•</caption>Do not take more than your prescribed dose. If you miss a dose, consult with your healthcare provider. </item>
                     <item>
                        <caption>•</caption>Call your healthcare provider if the dose you are taking does not control your pain. </item>
                     <item>
                        <caption>•</caption>If you have been taking belladonna and opium suppositories regularly, do not stop taking belladonna and opium suppositories without talking to your healthcare provider. </item>
                     <item>
                        <caption>•</caption>After you stop taking belladonna and opium suppositories, return unused suppositories to the pharmacy or deliver to an accredited disposal site. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.</item>
                     <item>
                        <caption>•</caption>Unwrap suppository, then moisten finger and suppository with water before inserting.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">While taking belladonna and opium suppositories DO NOT:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Drive or operate heavy machinery, until you know how belladonna and opium suppositories affects you. Belladonna and opium suppositories can make you sleepy, dizzy, or lightheaded. </item>
                     <item>
                        <caption>•</caption>Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with belladonna and opium suppositories may cause you to overdose and die.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">The possible side effects of belladonna and opium suppositories:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Get emergency medical help if you have:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.</item>
                  </list>
                  <paragraph>These are not all the possible side effects of belladonna and opium suppositories. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<content styleCode="bold"> For more information go to dailymed.nlm.nih.gov</content>
                  </paragraph>
                  <paragraph>Manufactured by Padagis<sup>®</sup>
                  </paragraph>
                  <paragraph>Minneapolis, MN 55427 </paragraph>
                  <paragraph>www.padagis.com or call 1-866-634-9120</paragraph>
                  <paragraph>Rev 04/2023</paragraph>
                  <paragraph>4D800 RC MG1</paragraph>
               </text>
               <effectiveTime value="20230809"/>
            </section>
         </component>
         <component>
            <section ID="ID_1aa5125d-82e8-492a-9025-ad2e30ccc117">
               <id root="88ac328f-8c90-4657-a0af-08b000ba9452"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </content>– <content styleCode="bold">Belladonna and Opium Suppository 16.2 mg/30 mg</content>
               </title>
               <text>
                  <paragraph>NDC 0574-7045-12</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Belladonna and Opium Suppositories</paragraph>
                  <paragraph>16.2 mg/30 mg</paragraph>
                  <paragraph>CII</paragraph>
                  <paragraph>Each suppository contains: Powdered Opium 30 mg</paragraph>
                  <paragraph>(Warning – May be habit forming)</paragraph>
                  <paragraph>Powdered Belladonna Extract 16.2 mg</paragraph>
                  <paragraph>Print Medication Guides at: www.padagis.com/medguide/BLOPB</paragraph>
                  <paragraph>12 Suppositories</paragraph>
                  <paragraph>UNIT DOSE</paragraph>
                  <paragraph>FOR RECTAL USE ONLY</paragraph>
                  <renderMultiMedia ID="id-501893146" referencedObject="ID_753546cd-5db4-45c8-b906-26ca0ec12aec"/>
                  <paragraph>The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.</paragraph>
                  <renderMultiMedia ID="id-1586751413" referencedObject="ID_35970944-4dc1-490f-9293-e0c6890430aa"/>
               </text>
               <effectiveTime value="20230809"/>
               <component>
                  <observationMedia ID="ID_753546cd-5db4-45c8-b906-26ca0ec12aec">
                     <text>16.2 mg/30 mg Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton-4d8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_35970944-4dc1-490f-9293-e0c6890430aa">
                     <text>serialization</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_dc8911e5-9bec-44dc-88be-936d3a868d2c">
               <id root="a5d11233-ce71-45ff-87b2-d7329e1a80e6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – Belladonna and Opium Suppository 16.2 mg/60 mg</title>
               <text>
                  <paragraph>0574-7040<content styleCode="bold">-</content>12</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Belladonna and Opium Suppositories</paragraph>
                  <paragraph>16.2 mg/60 mg</paragraph>
                  <paragraph>CII</paragraph>
                  <paragraph>Each suppository contains:  Powdered Opium 60 mg</paragraph>
                  <paragraph>(Warning – May be habit forming)</paragraph>
                  <paragraph>Powdered Belladonna Extract 16.2 mg</paragraph>
                  <paragraph>Print Medication Guides at: www.padagis.com/medguide/BLOPB</paragraph>
                  <paragraph>12 Suppositories</paragraph>
                  <paragraph>UNIT DOSE</paragraph>
                  <paragraph>FOR RECTAL USE ONLY</paragraph>
                  <renderMultiMedia ID="id60917991" referencedObject="BDE9C302-753A-4B06-BD28-885EFD444E3E"/>
                  <paragraph>The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.</paragraph>
                  <renderMultiMedia ID="id-1131092437" referencedObject="CF3144CC-B62F-4EAD-883E-16DB27222111"/>
               </text>
               <effectiveTime value="20230809"/>
               <component>
                  <observationMedia ID="BDE9C302-753A-4B06-BD28-885EFD444E3E">
                     <text>16.2 mg/60 mg Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton-7y6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="CF3144CC-B62F-4EAD-883E-16DB27222111">
                     <text>serialization</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>